CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based S-Trimer COVID-19 […]
Institut Pasteur researchers from the French organization’s Biology of Viral Emerging Infections Unit and its Viral Genomics and Vaccination Unit […]
Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical […]
Novavax Inc. (Nasdaq: NVAX) inked a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to supply up to […]
Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most […]
Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most […]
A number of scientists and patient advocacy groups share concern about the expedited approvals of two COVID-19 vaccine trials in […]
Led by Principal Investigator Dr. Scott McClelland and Dr. Anna Wald, the University of Washington School of Medicine (UW Medicine) […]
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its […]
Back in August, the UK and American vaccine maker Novavax announced an agreement to proceed to a Phase 3 clinical […]
